MannKind Mourns the Passing of Chairman Emeritus Alfred E. Mann
March 09 2016 - 7:46PM
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
today reported with deep sadness the passing of Alfred E. Mann, age
90, the company’s Chairman Emeritus. Mr. Mann was the
Chairman of the Board of MannKind from 2001 until February 2016
and, from November 2003 until January 2015, was its Chief Executive
Officer. Mr. Mann founded and largely funded 14 companies in
his career. Nine of these companies were acquired at an overall
total of almost $8 billion, and three companies became publicly
traded, MannKind being one of them. For nearly six decades, Alfred
Mann was a revolutionary voice and thinker in aerospace, medical
technology and biopharmaceuticals, and has led development of many
products to fill unmet and poorly met medical needs. Our
thoughts and condolences go out to Al's wife, Claude, his children,
and loved ones.
A photo accompanying this announcement is available
at http://www.globenewswire.com/NewsRoom/AttachmentNg/6d87a8dd-77bc-4068-a3a2-bafd43e79228
“Al has been a wonderful inspiration, not only
to me, but to all the employees of MannKind. His kindness,
generosity, and business acumen have influenced all of us with whom
he has done business and charitable work over the years. He
will be terribly missed by many, including the countless patients
around the world with diabetes and other serious illnesses, whose
lives he improved. I am thankful to have had a close
relationship with Al, and will reflect on his counsel and guidance
in the years to come. Our resolve is now stronger than ever
to continue Al's legacy of medical innovation, as a tribute to this
remarkable man, who did so much to help mankind,” said Matthew
Pfeffer, Chief Executive Officer of MannKind Corporation.
“Al's contribution to the diabetes field is
unparalleled, and he truly represents an iconic influence in the
philanthropic and business arena for our generation. I'm
honored to have worked for so many years with Al, and am proud to
have called him my friend,” said Kent Kresa, Chairman of the Board
of MannKind Corporation. No changes are anticipated in the
company’s day-to-day business activities. The company’s loan
agreement with The Mann Group is unaffected by the passing of Mr.
Mann.
JDRF Los Angeles tribute video:
https://youtu.be/Rs1BMRFlmqwAMI-USC tribute video:
https://youtu.be/SJg1hSfB7GQ
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD)
focuses on the discovery and development of therapeutic products
for patients with diseases such as diabetes. MannKind
maintains a website at http://www.mannkindcorp.com to which
MannKind regularly posts copies of its press releases as well as
additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its
reports with the Securities and Exchange Commission or posts
certain other information to the website.
Company Contact:
Matthew J. Pfeffer
Chief Executive Officer
661-775-5300
mpfeffer@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024